Smear test cost-effectiveness report delayed
This article was originally published in Clinica
Executive Summary
The Blue Cross and Blue Shield Association's Technology Evaluation Centre (TEC) has postponed its keenly awaited report on the clinical efficacy and cost-effectiveness of three new technologies to replace or improve Pap smear testing for cervical cancer.